A group B Streptococcus alpha-like protein subunit vaccine induces functionally active antibodies in humans targeting homotypic and heterotypic strains
(2022) In Cell Reports Medicine 3(2).- Abstract
Maternal vaccination is a promising strategy for preventing neonatal disease caused by group B Streptococcus. The safety and immunogenicity of the prototype vaccine GBS-NN, a fusion protein consisting of the N-terminal domains of the alpha-like proteins (Alp) αC and Rib, were recently evaluated favorably in healthy adult women in a phase 1 trial. Here we demonstrate robust immunoglobulin G (IgG) and immunoglobulin A (IgA) responses against αC and Rib, as well as against the heterotypic Alp family members Alp1–Alp3. IgA and heterotypic IgG responses are more variable between subjects and correlate with pre-existing immunity. Vaccine-induced IgG mediates opsonophagocytic killing and prevents bacterial invasion of epithelial cells. Like... (More)
Maternal vaccination is a promising strategy for preventing neonatal disease caused by group B Streptococcus. The safety and immunogenicity of the prototype vaccine GBS-NN, a fusion protein consisting of the N-terminal domains of the alpha-like proteins (Alp) αC and Rib, were recently evaluated favorably in healthy adult women in a phase 1 trial. Here we demonstrate robust immunoglobulin G (IgG) and immunoglobulin A (IgA) responses against αC and Rib, as well as against the heterotypic Alp family members Alp1–Alp3. IgA and heterotypic IgG responses are more variable between subjects and correlate with pre-existing immunity. Vaccine-induced IgG mediates opsonophagocytic killing and prevents bacterial invasion of epithelial cells. Like the vaccine-induced response, naturally acquired IgG against the vaccine domains is dominated by IgG1. Consistent with the high IgG1 cross-placental transfer rate, naturally acquired IgG against both domains reaches higher concentrations in neonatal than maternal blood, as assessed in a separate group of non-vaccinated pregnant women and their babies.
(Less)
- author
- organization
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- antibodies, group B Streptococcus, maternal immunization, neonatal disease, opsonophagocytosis, vaccines
- in
- Cell Reports Medicine
- volume
- 3
- issue
- 2
- article number
- 100511
- publisher
- Elsevier
- external identifiers
-
- scopus:85124518199
- pmid:35243418
- ISSN
- 2666-3791
- DOI
- 10.1016/j.xcrm.2022.100511
- language
- English
- LU publication?
- yes
- id
- 76eaa183-ef30-4e7e-8b6c-619951070e36
- date added to LUP
- 2022-04-13 11:44:51
- date last changed
- 2024-07-02 16:33:41
@article{76eaa183-ef30-4e7e-8b6c-619951070e36, abstract = {{<p>Maternal vaccination is a promising strategy for preventing neonatal disease caused by group B Streptococcus. The safety and immunogenicity of the prototype vaccine GBS-NN, a fusion protein consisting of the N-terminal domains of the alpha-like proteins (Alp) αC and Rib, were recently evaluated favorably in healthy adult women in a phase 1 trial. Here we demonstrate robust immunoglobulin G (IgG) and immunoglobulin A (IgA) responses against αC and Rib, as well as against the heterotypic Alp family members Alp1–Alp3. IgA and heterotypic IgG responses are more variable between subjects and correlate with pre-existing immunity. Vaccine-induced IgG mediates opsonophagocytic killing and prevents bacterial invasion of epithelial cells. Like the vaccine-induced response, naturally acquired IgG against the vaccine domains is dominated by IgG1. Consistent with the high IgG1 cross-placental transfer rate, naturally acquired IgG against both domains reaches higher concentrations in neonatal than maternal blood, as assessed in a separate group of non-vaccinated pregnant women and their babies.</p>}}, author = {{Pawlowski, Andrzej and Lannergård, Jonas and Gonzalez-Miro, Majela and Cao, Duojia and Larsson, Sara and Persson, Jenny J. and Kitson, Geoff and Darsley, Michael and Rom, Ane Lilleøre and Hedegaard, Morten and Fischer, Per B. and Johansson-Lindbom, Bengt}}, issn = {{2666-3791}}, keywords = {{antibodies; group B Streptococcus; maternal immunization; neonatal disease; opsonophagocytosis; vaccines}}, language = {{eng}}, number = {{2}}, publisher = {{Elsevier}}, series = {{Cell Reports Medicine}}, title = {{A group B Streptococcus alpha-like protein subunit vaccine induces functionally active antibodies in humans targeting homotypic and heterotypic strains}}, url = {{http://dx.doi.org/10.1016/j.xcrm.2022.100511}}, doi = {{10.1016/j.xcrm.2022.100511}}, volume = {{3}}, year = {{2022}}, }